Patent intelligence · US
US 11957677
Cancer treatment using FGFR inhibitors and PLK1 inhibitors
Cancer treatment using FGFR inhibitors and PLK1 inhibitors
Patent details — US 11957677
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 16, 2024
- Expiration
- Apr 11, 2044
- Applicant
- Cardiff Oncology, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K31/496, A61K31/5025, A61K31/506
Quick answer
US 11957677 (Cancer treatment using FGFR inhibitors and PLK1 inhibitors) is held by Cardiff Oncology, Inc.. Status: granted. Granted Apr 16, 2024. Expires Apr 11, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cardiff Oncology, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/496, A61K31/5025, A61K31/506, A61K31/517, A61K31/519
More from Cardiff Oncology, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12383540
Compounds that modulates AMPA receptor function
granted -
US 12318418
Modified adenoviruses
granted -
US 12263173
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
granted -
US 12144813
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
granted -
US 12053513
Cancer-specific T-cell receptors
granted -
US 11850264
Gamma delta T-cell receptor and its ligand
granted -
US 11725039
α/β t-cell receptor and methods of using it
granted
Frequently asked questions
What is US patent 11957677?
US 11957677 (Cancer treatment using FGFR inhibitors and PLK1 inhibitors) is held by Cardiff Oncology, Inc.. Status: granted. Granted Apr 16, 2024. Expires Apr 11, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11957677?
Cardiff Oncology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 11957677 expire?
Our index shows an expiration date of Apr 11, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.